Laskin J - Search Results

1

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. Schuler M, et al. Among authors: laskin j. J Cancer Res Clin Oncol. 2019 Jun;145(6):1569-1579. doi: 10.1007/s00432-019-02862-x. Epub 2019 Feb 19. J Cancer Res Clin Oncol. 2019. PMID: 30783814 Free PMC article. Clinical Trial.

2

Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America.

Ho C, Murray N, Laskin J, Melosky B, Anderson H, Bebb G. Ho C, et al. Among authors: laskin j. Lung Cancer. 2005 Aug;49(2):225-31. doi: 10.1016/j.lungcan.2005.02.011. Lung Cancer. 2005. PMID: 15925429

3

The role of prophylactic cranial radiation in the treatment of non-small-cell lung cancer.

Laskin JJ, Sandler AB. Laskin JJ, et al. Clin Adv Hematol Oncol. 2003 Dec;1(12):731-34. Clin Adv Hematol Oncol. 2003. PMID: 16258477 Review.

4

First-line treatment for advanced non-small-cell lung cancer.

Laskin JJ, Sandler AB. Laskin JJ, et al. Oncology (Williston Park). 2005 Nov;19(13):1671-6; discussion 1678-80. Oncology (Williston Park). 2005. PMID: 16425521 Review.

5

Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.

Pugh TJ, Bebb G, Barclay L, Sutcliffe M, Fee J, Salski C, O'Connor R, Ho C, Murray N, Melosky B, English J, Vielkind J, Horsman D, Laskin JJ, Marra MA. Pugh TJ, et al. Among authors: laskin jj. BMC Cancer. 2007 Jul 13;7:128. doi: 10.1186/1471-2407-7-128. BMC Cancer. 2007. PMID: 17626639 Free PMC article.

6

Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy.

Dong X, Guan J, English JC, Flint J, Yee J, Evans K, Murray N, Macaulay C, Ng RT, Gout PW, Lam WL, Laskin J, Ling V, Lam S, Wang Y. Dong X, et al. Among authors: laskin j. Clin Cancer Res. 2010 Mar 1;16(5):1442-51. doi: 10.1158/1078-0432.CCR-09-2878. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179238

7

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.

Gervais R, Hainsworth JD, Blais N, Besse B, Laskin J, Hamm JT, Lipton A, Albain KS, Masters GA, Natale RB, Selaru P, Kim ST, Chao RC, Page RD. Gervais R, et al. Among authors: laskin j. Lung Cancer. 2011 Dec;74(3):474-80. doi: 10.1016/j.lungcan.2011.05.004. Epub 2011 Jun 15. Lung Cancer. 2011. PMID: 21680048 Clinical Trial.

8

Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).

Laskin J, Crinò L, Felip E, Franke F, Gorbunova V, Groen H, Jiang GL, Reck M, Schneider CP. Laskin J, et al. J Thorac Oncol. 2012 Jan;7(1):203-11. doi: 10.1097/JTO.0b013e3182370e02. J Thorac Oncol. 2012. PMID: 22173662 Free article. Clinical Trial.

9

Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.

Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D. Laskin JJ, et al. J Thorac Oncol. 2012 Mar;7(3):579-86. doi: 10.1097/JTO.0b013e31823f459c. J Thorac Oncol. 2012. PMID: 22198426 Free article. Clinical Trial.

10

Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC).

Jagdis A, Laskin J, Hao D, Hay J, Wu J, Ho C. Jagdis A, et al. Among authors: laskin j. Am J Clin Oncol. 2014 Feb;37(1):63-9. doi: 10.1097/COC.0b013e31826b9b1a. Am J Clin Oncol. 2014. PMID: 23111356

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

780 results

Search Page

Filters